Mechanism of action and pharmacologic effects
Alteplase is a recombinant analogue of natural tissue-type plasminogen activator (tPA). Unlike modified complexes (e.g., anistreplase, where the catalytic center of plasminogen is temporarily blocked by an acyl group to create a prodrug effect), Alteplase acts directly.
A key pharmacological feature of the drug is selectivity. The drug has little effect on plasminogen circulating in the systemic bloodstream. Activation occurs locally: the drug converts inactive plasminogen into the active enzyme plasmin predominantly in the area of the thrombus. The resulting plasmin destroys the fibrin framework, leading to rapid lysis (dissolution) of the thrombus and restoration of blood flow.
Indications for use
The drug is used in emergency cardiology and intensive care for thrombolytic therapy. The main indications include:
- Acute myocardial infarction (coronary thrombosis). The time factor is critical here: the clinical efficacy of thrombolysis is highest when the drug is administered intravenously within the first 6–12 hours from the onset of the cardiac event.
- Pulmonary embolism (PE) — a life-threatening condition requiring immediate elimination of occlusion in the pulmonary vasculature.
Side effects and risks
Although alteplase is selective and depletes the systemic plasminogen pool significantly less than non-selective activators (such as Streptokinase or Urokinase), it is not completely safe.
The main risk with any fibrinolytic is hemorrhagic complications. The probability of developing severe, including life-threatening bleeding persists, which requires careful patient selection, exclusion of contraindications, and strict monitoring in an intensive care unit.
Dosage form and prescription rules
The drug is available as a dry substance (lyophilisate). Vials contain 0.05 g of the active substance.
Preparation and administration rules:
- Prior to intravenous administration, the contents of the vial (0.05 g) must be dissolved strictly in 50 ml of water for injections.
- Administered strictly intravenously.
- The dosing regimen and infusion rate are strictly individual and depend on the specific clinical situation (administration protocols for acute myocardial infarction and pulmonary embolism differ).
Prescription writing example:
Rp.: Alteplasi 0.05 D.t.d. N. 1 S. Intravenously. Dissolve the contents of the vial in 50 ml of water for injections. Administer according to an individual schedule.
Briefly: answers to topical questions
What are the indications for use of alteplase?
Indications for the use of the recombinant tissue-type plasminogen activator alteplase include acute thrombotic conditions requiring intravenous administration of the drug. The main indications include:
- Acute myocardial infarction — coronary thrombosis (the highest clinical efficacy of the drug is observed when used within the first 6–12 hours).
- Pulmonary embolism — PE.
What side effects does alteplase cause?
The main side effect of the intravenous use of the recombinant alteplase preparation is the development of bleeding. Despite the selectivity of action of this tissue-type plasminogen activator and its relatively minor effect on circulating plasminogen in the systemic bloodstream, the risk of hemorrhagic complications persists during thrombolytic therapy.
What drugs are antagonists (antidotes) of alteplase in case of bleeding?
For bleeding associated with the use or overdose of fibrinolytics, antifibrinolytic agents are used that inhibit plasminogen activation or directly inhibit plasmin. These include:
- Aminocaproic acid — binds to plasminogen, blocks its conversion to plasmin, and prevents the action of already formed plasmin on fibrin.
- Aminomethylbenzoic acid — an analogue of aminocaproic acid with a similar mechanism of action.
- Tranexamic acid — inhibits plasminogen activation.
- Aprotinin — inhibits plasmin and other proteolytic enzymes.
ALTEplase — ALTErnative to streptokinase: acts on tissue plasminogen (tPA), dissolves blood clots in acute myocardial infarction and pulmonary embolism.
Class and exam questions
What is the main difference between alteplase and streptokinase?
Alteplase is a recombinant tissue activator; it acts more selectively, predominantly activating fibrin-bound plasminogen within the thrombus. Streptokinase, on the other hand, is non-selective and activates plasminogen systemically throughout the bloodstream.
What is the therapeutic window in myocardial infarction?
The drug is most effective if intravenous administration is initiated within the first 6–12 hours after the development of coronary thrombosis. Later on, efficacy decreases and risks increase.
Does the selectivity of alteplase eliminate the risk of bleeding?
No. Despite its minor effect on circulating plasminogen, the risk of severe hemorrhagic complications during alteplase therapy remains high.
How does the prodrug principle work using the example of anistreplase (compared to alteplase)?
In anistreplase, the catalytic center is temporarily blocked by an acyl group, and plasmin activation occurs only after deacylation (after 40 minutes). Alteplase lacks such a block and begins to act immediately after administration.
What else to study on this topic
- Comparative pharmacokinetics of recombinant drugs: alteplase and tenecteplase.
- Mechanism of fibrin formation and degradation: the role of plasminogen and plasmin.
- Absolute and relative contraindications to thrombolytic therapy.
- Anistreplase: the prodrug concept and the effect of the acyl group on activation rate.
- Complications of thrombolysis: protocols for managing hemorrhagic syndrome.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Alteplase" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.